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Abstract
Fontan operation as the current ultimate palliation of single ventricle defects results in significant late complications eventually
leading to a failing circulation. It has been suggested that introducing a cavopulmonary assist device to serve the function of
the missing subpulmonary ventricle could potentially stabilize the failing Fontan circulation. The objective of this study is to
identify the desired operating region for a cavopulmonary blood pump that can offer a promising alternative treatment option for
a wide range of failing Fontan patients. By integrating numerical analysis and available clinical information, the interaction of the
cavopulmonary support (producing head pressure rise from 2-20mmHg) via the IVC and full assist configurations with a wide
range of simulated adult failing patient cases was investigated; with IVC and full assist corresponding to the inferior venous return
or the entire venous return, respectively, being routed through the device. We identified the desired hydraulic operating regions
for a cavopulmonary assist device by clustering all head pressures and corresponding pump flows that result in hemodynamic
improvement for each simulated failing Fontan physiology. The results presented here can serve as the performance criteria for
designing cavopulmonary assist devices as well as evaluating off-label use of commercially available left-side blood pumps for
failing Fontan cavopulmonary support.
Index Terms
Right support, lumped parameter model, Simulation, Fontan failure.
I. INTRODUCTION
TREATMENT of single ventricle defects involves three stages of surgeries and is concluded with the Fontan operation.The Fontan operation involves diverting the entire systemic venous return directly to the pulmonary arterial tree via the
formation of the total cavopulmonary connection (TCPC). While the Fontan procedure has resulted in survival of single ventricle
patients into adulthood and reduced early morbidity and mortality, the lack of the subpulmonary ventricle to drive the flow
forward into the lungs and the pressure loss across the TCPC (approximately 1-5mmHg) have led to a myriad of serious late
complications for these patients. For instance, excessive hepatic venous pressure in these patients leads to complications such as
hepatic cirrhosis, hepatic fibrosis, and eventual liver failure [1]. The cardiac performance of Fontan patients varies widely, and
these patients hemodynamic conditions depend on several factors, including systemic and pulmonary vascular resistances. A
significant number of patients following the Fontan operation (post-operation>15 years; age: 23±7 years [2]) ultimately develop
circulatory failure. The failing stage in these patients is traditionally characterized by significant hemodynamic anomalies such
as high caval pressure, low cardiac output, and low arterial oxygen saturation [3–5]. Recently, in addition to the traditional
class of failing Fontan patients, a new failing Fontan phenotype class with high caval pressure and normal cardiac output has
been recognized [6–8]. Despite normal cardiac output, this failing Fontan class is sicker compared to the traditional group,
possibly due to more severe liver-related complications [9]. While some researchers have found no association between Fontan
related liver complications and cardiac output [10], others have suggested liver fibrosis and hepatic arterialization as a cause
for the higher cardiac output in this group of failing Fontan patients [11]. In general, previous studies have shown that many
of the Fontan related complications are connected to chronically high caval pressure [12]. The growing population of Fontan
patients suffering from life-threatening late complications signifies the importance of undertaking engineering and medical
efforts to address the unmet therapeutic need and ameliorate limitations of the Fontan circulation. In 1998, de Leval [13]
proposed the use of a mechanical cavopulmonary assist device to substitute the function of the absent subpulmonary ventricle
as a solution for reducing the caval pressure and augmenting the ventricular filling in a failing Fontan circulation. Several
studies have shown that a cavopulmonary assist device could benefit the hemodynamics by decreasing the inferior vena caval
(IVC) pressure and promoting the cardiac output [14–20]. For instance, Hsu et al. [21] presented a prototype cavopulmonary
assist device (viscous impeller pump) and used numerical simulations to show that this device implanted in the TCPC could
decrease the IVC pressure by 16% while improving the cardiac output by 36%. In another computational study, Shimizu et
al. [22] also confirmed a reduction of the IVC pressure and increase of cardiac output by the presence of a cavopulmonary
assist device in the IVC. Molfetta et al. [23] simulated the physiology of 10 failing Fontan cases and quantified an average
of 34% increase and 39% decrease in the cardiac output and IVC pressure, respectively, with the presence of a right side
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2TABLE I: Mean values of the hemodynamic parameters from simulations of the 6 example Fontan patients at baseline.
Parameters Range
BSA (m2) [1.27-2.3]
Cardiac output (L.min−1) [3.37-5.79]
Arterial pressure(mmHg) [91.98-97.10]
Atrial pressure(mmHg) [8.90-9.92]
Pulmonary pressure (mmHg) [13.37-14.50]
IVC pressure (mmHg) [13.37-14.50]
support device. Nonetheless, there is currently no pump commercially available for the cavopulmonary application and right
side support is not used in the clinical management of Fontan patients. Additionally, in an earlier study [24], it was shown
that there are risks associated with using a commercially available left ventricular assist device (VAD) for cavopulmonary
support in single ventricle patients, because the pressure level in the cavopulmonary pathway is approximately 90% lower
compared to the left side arterial environment; a left VAD typically generates a head pressure of ≈37 to 80mmHg for flow
rates ranging approximately from 0.5 to 6L.min−1 and the high head pressure produced by a left VAD implanted on the
right circulation may result in pulmonary arterial tree perfusion damage and central venous collapse. A suitably designed
cavopulmonary assist device should be versatile enough to serve a wide range of failing Fontan patients with various levels of
hemodynamic instability. The objective of this study is to identify the desired operating region for such a device. In this study,
we classified hemodynamic failure in Fontan patients into two groups: 1) traditional failure with low cardiac output concurrent
with chronic high caval pressure and 2) failure with chronic high caval pressure concurrent with normal cardiac output. Each
group encompasses physiologic cases with various hemodynamic states. We developed numerical models to simulate a full
range of failing stage Fontan physiologies in each phenotype class reflecting pathological conditions with various severity levels
of systolic dysfunction, diastolic dysfunction, and abnormal systemic and pulmonary vascular resistances. The Fontan patient
physiologic cases with different hemodynamic conditions were modeled to represent at least 95% of patients in both failing
phenotype groups. Next, a cavopulmonary assist device generating a range of head pressure rises (from 2 -20mmHg) during
full and IVC support was modeled for each physiologic case. In each simulated case, we identified the pump head pressures
and the resulting pump flows (P-Q data points) that produce hemodynamic improvement, signified by reduced IVC pressure
(most important) and other desirable hemodynamic changes. Lastly, we identified the desired operating regions for designing
a cavopulmonary assist device suitable for the full or IVC support by clustering all of the P-Q data points that resulted in
hemodynamic improvement in each simulated failing Fontan physiology.
II. METHODS
A. Physiology model of the healthy Fontan circulation (Baseline)
In an earlier study, we used clinical and physiological data from healthy Fontan patients to develop and validate a closed-loop
lumped parameter network (LPN) model for describing the healthy Fontan circulation (Fig. 1). The computational model is
tuned based on patient weight and height and prescribes the cardiac function and pulmonary and systemic vascular impedances
according to the patients body size. It was shown that the physiology model produces accurate trends in physiological
parameters [25]. The heart block produces the pressure needed for driving the flow through the circuit. The cardiac function for
generating the transmyocardial pressure is described using (1) and (2). E(t) is the ventricular time-dependent elastance; En(t)
is the normalized elastance function; Emax, and Eoffset are constants related to contractility (as well as ventricular ejection
fraction) and ventricular filling (and ventricular stiffness), respectively. t describes the time point in the cardiac cycle period
and tsvs is the cardiac systolic period. Ventricular volume and reference volume are Vsv and Vsv0, respectively.
Psv(Vsv, t) = E(t)(Vsv − Vsv0) (1)
E(t) = EmaxEn(
0.3
tsvs
t) + Eoffset (2)
Table I details the range of time-averaged values of selected physiologic parameters of six healthy Fontan patients (baseline)
with various body sizes. The parameters used for setting the LPN component values for each patient at the baseline are derived
according to our previous study [25].
B. Patients with hemodynamic failure
There are several determinants which influence hemodynamic parameters such as cardiac function and the aberration level
of systemic and pulmonary vascular resistances. To include a wide range of patient cases for each phenotype group, for
each of the six patient body size baseline models, we simulated different physiologic cases with different level of pulmonary
and systemic vascular resistances and severity of systolic and diastolic dysfunctions. Ohuchi et al. [2] and Cavalcanti et
al. [26] have evaluated the hemodynamics in adult failing Fontan patients and presented a broad range of clinically measured
3Fig. 1: Closed-loop lumped parameter model of the Fontan circulation. Pressure points (Psub) are labeled on the diagram. Lsub
and Rsub are inductor and resistor components, respectively [25].
physiologic values of cardiac index and arterial and IVC pressures for failing patients as mean value with 1 standard deviation
(SD). We modeled physiologic cases in each phenotype class such that the range of simulated scenarios (e.g., cardiac
index, arterial pressure, IVC pressure) cover approximately 2SD of those clinically measured parameter values; based on the
three-sigma rule, 2SD from the mean value encompasses ≈95% of the population values [27].
1) Group I (Failing patients with high caval pressure and low cardiac output): This phenotype is well recognized. The
circulation in this class of patients generally deteriorates as a result of systolic dysfunction, diastolic dysfunction, and high
pulmonary vascular resistance [2], [8], [28]. Therefore, we simulated this phenotype by reducing ventricular contractility
(Emax, representing ventricular systolic function), increasing ventricular stiffness (Eoffset, representing ventricular diastolic
function) and increasing pulmonary vascular resistance (PVR). These values were incrementally changed to model various
severity levels of hemodynamic aberration according to the following protocol:
1) The range of Emax was defined to start at the baseline value and end at the value that results in an ejection
fraction of 30% [23] (which corresponds to a specific cardiac output).
2) While Emax was held constant at its baseline value, the range of Eoffset was defined to start at the baseline value and
end at the value that results in the cardiac output obtained at the end of step (1).
3) Similarly, while Emax and Eoffset were maintained at their baseline values, PVRs´ range was defined to start at its baseline
value and end at the value that results in the cardiac output obtained at the end of step (1).
4) A number of equally spaced levels for each input variable (PV R, Emax, Eoffset) over their ranges, as determined in steps
(1-3), were used in all possible permutations to simulate a wide range of possible failing physiologic cases.
5) Next, selected physiologic parameters (IVC pressure, cardiac index, and arterial pressure) from each simulated case were
evaluated against clinical catheterization data from failing Fontan patients reported by Cavalcanti et al. [26].
The simulated cases where the selected physiologic parameters laid outside of approximately 2SD of the mean value of the
clinical catheterization data were discarded. This resulted in 750 simulated patient cases for group I.
2) Group II (Failing patients with high caval pressure and normal cardiac output): To our knowledge, there exists
currently no mathematical circulation model available for this group. The pathophysiology related to this class of patients is
not well understood. While the cardiac function in this group of patients is normal, the systemic vascular resistance (SVR) is
abnormally low. Moreover, contrary to the traditional group of failing Fontan patients, the pulmonary vascular resistance in
these patients is often low [8]. To simulate this class of Fontan failures, we decreased the systemic and pulmonary vascular
resistances over a wide region from their baseline values while maintaining normal ventricular systolic and diastolic function.
4Fig. 2: Schematic representation of the (A) Full support and (B) IVC support. LPA is left pulmonary artery, RPA is right
pulmonary artery SVC is superior vena cava, IVC is inferior vena cava.
There is limited information on the level of systemic and pulmonary vascular resistance aberration in this recently recognized
group of failing patients. Therefore, we investigated the SVR and PVR values in our models such that the selected physiologic
parameters from simulations cover 2SD of the mean value of the clinical data through the following steps:
1) The region of interest of SVR was defined to start from its baseline value (SV R0) and end at 10% of SV R0 .
10 equally spaced levels for SVR over its region of interest were taken.
2) The region of interest of PVR was defined to start from its baseline value (PV R0) and end at 20% of PV R0 . 10 equally
spaced levels for PVR over its region of interest were taken.
3) Similar to the procedure used for group I, we compared the simulated physiologic cases in group II with clinical data from
group II failing patients reported by Ohuchi et al. [2] and removed physiologic cases that were outside of 2SD of the mean
value of the clinical data. These steps resulted in 495 simulated patient cases for group II.
C. Desired operating regions for cavopulmonary assist device
We modeled the implementation of the cavopulmonary support via IVC and full assist surgical configurations (Fig. 2). For
each patient case, we simulated device head pressure rises from 2-20mmHg (in 0.5mmHg increments), resulting in overall
approximately 60,000 simulations. High caval pressure is the main determinant of Fontan related diseases. Thus, for each
simulated case, the head pressures and the resultant corresponding pump flows that led to a decrease in the caval pressure
while maintaining other physiologic pressures in safe ranges were identified. Hemodynamic improvement was defined as at
least 2mmHg reduction in the IVC pressure while maintaining a pulmonary pressure of <22mmHg [29] (to avoid pulmonary
arterial hypertension and lung perfusion damage), an atrial pressure of <16mmHg, [30] superior vena caval (SVC) pressure
<20mmHg (to avoid precipitous increase in the SVC pressure and potential cerebral damage), and mean IVC pressure >4mmHg
(to avoid potential IVC collapse). Finally, the data points corresponding to the head pressures and pump flows that resulted in
hemodynamic improvement in each physiologic case were clustered to form the desired operating regions. The flow diagram
(Fig. A.1) in Appendix A summarizes the process for identifying the desired operating regions.
III. RESULTS
A. Patients with hemodynamic failure
Comparing the simulation results against the catheterization information reported in Cavalcanti et al. [26] for group I
and Ohuchi et al. [2] for group II of Fontan failures, the range of selected physiologic parameters for the simulated cases
encompasses a 2SD range of the values of those parameters measured clinically in Fontan failures in group I and II (Fig. 3).
The simulations show an elevation of the IVC pressure in both groups, ranging from 14.16-25.23mmHg for group I and
11.48-22.48mmHg for group II. In group I, the cardiac index also decreased, ranging from 0.72-2.65L.min−1.m−2. Conversely,
in group II, the cardiac index increased ranging from 2.71-6.00L.min−1.m−2. However, concurrent with increased cardiac
index, a significant elevation of the IVC pressure in group II was observed, which is consistent with previous reports in this
group of patients [3], [31]. The simulated systemic arterial pressure in group I and II were within 47.54-97.1mmHg and
53.12-114.71mmHg, respectively. Simulations show an increase of the atrial pressure in both groups of Fontan failures which
aligns with literature reports [2], [23], [26].
5Fig. 3: Range of the selected hemodynamic parameters (pre-support) from simulations and reported catheterization data of the
group I and II failing Fontan physiologic cases. CI: cardiac index, IVC pressure: inferior vena caval pressure, SD: Standard
deviation.
Fig. 4: Desired operating regions of (A) IVC and (B) full assist cavopulmonary devices suitable for serving a wide range of
failing Fontan patients in group I and II phenotype classes.
B. Desired operating regions for cavopulmonary assist device
We obtained the desired head pressureflow operating regions of the IVC and full cavopulmonary assist supports that properly
serve a wide range of failing Fontan patients in each phenotype class (Fig. 4). Depending on the patients class (group I or
group II) and surgical configuration for installation of the cavopulmonary assist, a device should be designed such that its
characteristic curves at different pump speeds can encompass the entire desired operating region. Our results show that during
full support for group I and II populations, the head pressure generated by the cavopulmonary device should not exceed
15mmHg and 17.5mmHg, respectively. During IVC support, the head pressures required are smaller than 11.5mmHg and
16mmHg for group I and II, respectively. We identified the simulated physiologic cases in each phenotype group that the
presence of the cavopulmonary pump can lead to hemodynamic improvement (Fig 5). Cavopulmonary support did not benefit
either group if the patients pre-support IVC pressure >≈21mmHg (full support) or >18.5mmHg (IVC support).
C. Hemodynamic response to cavopulmonary support
Based on simulation results for the physiologic cases that favorably responded to the cavopulmonary support, the presence of
the cavopulmonary assist promoted the cardiac index, pulmonary pressure and decreased the IVC pressure (Fig. 6). Furthermore,
we noticed that the positive hemodynamic response was confined by the pre-support hemodynamic condition and the head
pressure level generated by the cavopulmonary device. For instance, the cardiac index increase was 5-45% (5-35%) for group
I and 5-36% (5-32%) for group II via full support (IVC support). The IVC pressure as a crucial parameter, also favorably
decreased across both groups by the presence of the cavopulmonary assist. Overall, the maximum favorable reduction of the
IVC pressure was ≈65% and ≈70% via full support and IVC support, respectively. The IVC pump increased the SVC pressure,
whereas the SVC pressure decreased via full support.
6Fig. 5: Range of selected hemodynamic parameters (pre-support) of physiologic cases characterized as group I (Solid lines)
and group II (Dashed lines) that favorably responded to the IVC and full cavopulmonary support.
Fig. 6: Response range (%) of the selected hemodynamic parameters of simulated physiologic cases to the IVC and full
cavopulmonary support. CI: Cardiac index; Pivc: IVC pressure; Ppul: Pulmonary pressure; Psa: atrial pressure.
IV. DISCUSSION
The present study aimed to identify the desired operating regions for a cavopulmonary blood pump that can support the failing
Fontan circulation. The identified desired operating regions could assist manufacturers in designing a right side assist device
suitable for IVC or full support surgical configurations and for different classes of Fontan failures. To obtain these operating
regions, a numerical analysis was performed investigating the interaction of a cavopulmonary assist device with a broad range
of the possible failing Fontan physiologic cases. In this study, presence of cavopulmonary support in two groups of failing
Fontan patients was investigated. Both groups of the patients have high caval pressure, however, the patients with a combination
of normal cardiac index and high caval pressure have worse long-term survival based on clinical experience [9]. Liver injury
is significantly correlated with high caval pressure and the abnormally low systemic vascular resistance in these patients is
hypothesized to be because of liver complications. The reduced afterload in this group of patients significantly contributes to
the cardiac index level. Even though these patients have normal cardiac output and don’t need cardiac output augmentation,
presence of a cavopulmonary device will reduce the caval pressure and may result in alleviating liver dysfunction [32]. Therefore,
reversing the liver damage could potentially stabilize the systemic vascular resistance and cardiac output (due to increased
afterload) in long-term. This notion requires further investigation. Previous pioneering studies on short term Fontan animal
models have highlighted the importance of designing a proper mechanical assist device for right side support by recognizing
the problems such as IVC collapse associated with off-label use of a left VAD for cavopulmonary application [33–35]. For
example, Riemer et al. [33] investigated the impact of the right support using a left VAD (Thoratec HeartMate II, Thoratec
Corporation, Calif) in 8 sheep and they observed decrease of the IVC flow as a result of IVC collapse and low IVC pressure
(-0.25±0.48mmHg) in all animals. Due to the risks of human trials involving cavopulmonary support, numerical models have
been widely used to study the Fontan circulation and its interaction with right side support. We previously developed and
verified a closed-loop LPN of the physiology model of the Fontan circulation capable of simulating dynamic physiologic
response to changes in the circulation [25]. These types of computational models have been used to study the hemodynamic
response of Fontan circulation to a left [36] or right [37] VAD. We studied two previously suggested surgical configurations
for the installation of the cavopulmonary assist device (IVC and full support) [22] and identified a range where hemodynamic
improvement is possible for each patient case via full or IVC support. The optimal operating point specific to each patient lies
in this range and a full or IVC cavopulmonary device should be capable of covering this range for every patient case to allow
a clinician to find the optimal point for any patient. Simulations show that a proper cavopulmonary device for the traditional
7Fig. 7: Desired operating regions of (A) IVC and (B) full assist cavopulmonary devices overlaid with characteristics curves of
a left VAD and a cavopulmonary intravascular blood pump.
group of failing Fontan patients (group I) only needs to cover a small operating region. However, for the newly recognized
phenotype group, the desired operating region covers a larger area that may complicate the design of a cavopulmonary device.
The results of our current study can also be used to evaluate the performance of the available cavopulmonary prototype devices
as well as off-label use of commercially available left VADs for cavopulmonary applications. Researchers in recent years have
investigated several cavopulmonary devices for supporting the failing Fontan circulation. Throckmorton et al. [38] proposed
an intravascular blood pump for the IVC support configuration. As the intravascular blood pump (at 4000rpm) generates a
pressure increase of 2.5-9.5mmHg for the flows rates of 2-6L.min−1, its performance curve only covers parts of the full and
IVC support desired operating regions (Fig. 7) which suggests that this intravascular cavopulmonary blood pump at 4000rpm
can serve some of the failing patients. On the other hand, The characteristic curve of the Jarvik 2000 at 4400rpm [39] lies
almost entirely outside of the full supports desired operating region (Fig. 7). Therefore, the Jarvik 2000 at this speed is not
a suitable candidate for full cavopulmonary support. This finding is consistent with our previous study [24] that showed the
Jarvik 2000 at 4400rpm caused extra resistance and obstructed the cavopulmonary pathway which resulted in an unfavorable
increase in the IVC pressure. Nonetheless, for a limited flow range of 1.5-2.55L.min−1, the performance curve at 4400rpm is
partly inside the IVC support desired operating region indicating that the pump can possibly serve some failing Fontan patients
in the IVC support implementation, also consistent with our previous finding [24].
V. CONCLUSION
This study presents the hydraulic operating regions for manufacturing a cavopulmonary blood pump specifically designed
for helping failing Fontan patients. We simulated and investigated the interaction of a cavopulmonary assist device (generating
head pressure from 2 to 20mmHg) with a full range of failing stage Fontan physiologies reflecting pathological conditions
with various severity levels of systolic and diastolic dysfunction and abnormal pulmonary and systemic vascular resistances,
representing approximately 95% of the adult failing Fontan population. The results show that a cavopulmonary assist device
could increase cardiac index by 5-45% and decrease the IVC pressure by 5-70% depending on the patients pre-support
hemodynamic state and surgical configuration of the cavopulmonary assist device (IVC or full support). Overall, according to
the identified desired operating region, the IVC support pump should be capable of generating a head pressure of 2-11.5mmHg
for flows of 1.5-≈4L.min−1 in failing Fontan patients with low cardiac output and high IVC pressure (group I). For the newly
recognized failing class of Fontan patients with normal cardiac output and high IVC pressure (group II), a device should be
able to create head pressures of 2-16mmHg for flows of ≈2-11L.min−1. However, the device should cover a wider range for
both groups when providing full support. The full support desired operating region shows the full assist pump should be able
to produce a head pressure of 2-15mmHg for flows of 2-6.5L.min−1 and ≈2-17.5mmHg for flows of 4-14L.min−1 for group
I and II, respectively. Additionally, we identified physiologic cases where IVC or full cavopulmonary support harmed rather
than benefited hemodynamic conditions, predisposing these physiologic cases to perfusion lung damage or venous collapse
as a result of pressure generated by the cavopulmonary device. These physiologic cases were excluded and were not used
for obtaining the desired operating regions. These results may help serve as guidelines for identifying patient characteristics
unsuitable for cavopulmonary support.
APPENDIX A
FLOW DIAGRAM ILLUSTRATING THE PROCEDURE FOR OBTAINING A DESIRED OPERATING REGION
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8Fig. A.1: Flow Diagram illustrating the procedure for obtaining a desired operating region.
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